Drug Profile

TRB 002

Alternative Names: TRB-002

Latest Information Update: 11 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Trican Biotechnology
Class Bispecific antibodies; Eye disorder therapies
Mechanism of Action Angiogenesis inhibitors; Complement system protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

08 Jan 2025 Discontinued - Preclinical for Age-related macular degeneration in Taiwan (Parenteral), before December 2024 (Trican Biotechnology pipeline, December 2024)
28 Jul 2024 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Taiwan (Parenteral)
08 Jun 2020 Preclinical trials in Age-related macular degeneration in Taiwan (Parenteral), prior to June 2020 (Trican Biotechnology pipeline, June 2020)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com